Scholarlink

Purpose <p>This study aimed to formulate and clinically evaluate a novel lipid liquid crystal (LLC) dressing containing eugenol and iodoform, designed for sustained release, antimicrobial activity, and pain relief in alveolar osteitis (AO).</p> Methods <p>Formulations with varying ratios of phosphatidylcholine (PC), sorbitan monooleate (SMO), glyceryl monooleate (GMO), and N-methyl-2-pyrrolidone (NMP) were prepared. The formulation which showed a good physicochemical stability and suitable viscosity was selected for further studies (F17, the optimized formulation). The optimized formulation was characterized for physicochemical properties and in vitro release. In a double-blind, randomized trial with 60 AO patients, the LLC-dressing was compared to Alvogyl<sup>®</sup> for pain, analgesic use, and dressing applications over seven days.</p> Results <p>The optimized formulation (F17) contained 35.25% PC, 35.25% SMO, 13.7% eugenol, and 15.8% iodoform, demonstrating an improved sustained drug release profile, appropriate viscosity, effective antibacterial activity, 100% encapsulation efficiency, and drug loading of 13.7% (eugenol) and 15.8% (iodoform). Visual Analog Scale (VAS) pain scores were comparable between LLC-dressing and Alvogyl<sup>®</sup> at all assessed time points, with no significant differences (0&#xa0;h: 8.14 ± 1.40 vs. 7.96 ± 1.02; 7 days: 0.70 ± 0.66 vs. 0.78 ± 0.60; <i>p</i> &gt; 0.05). Analgesic use (5.51 ± 3.06 vs. 6.13 ± 2.87, <i>P</i> = 0.401) and dressing applications (2.27 ± 1.12 vs. 2.57 ± 1.20, <i>P</i> = 0.345) showed similar efficiency.</p> Conclusion <p>The optimized LLC-dressing (F17) exhibits favorable physicochemical and in vitro characteristics and may be considered a potential alternative to Alvogyl<sup>®</sup> for the management of AO.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Eugenol- and Iodoform-Loaded Lipid Liquid Crystal Dressing for Alveolar Osteitis: Formulation, In Vitro Evaluation, and a Double-Blind Randomized Clinical Trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月10日

查看全文
  • Ali Asghar Khakshur,
  • Mohammadreza Abbaspour,
  • Alireza Mirshahi,
  • Amirhossein Chavoshi,
  • Mahdi Gholami,
  • Hossein Bagheri,
  • Vahid Soheili,
  • Pouria Rahmanian-Devin,
  • Hossein Kamali,
  • Kofi Asare-Addo,
  • Ali Nokhodchi

摘要

Purpose

This study aimed to formulate and clinically evaluate a novel lipid liquid crystal (LLC) dressing containing eugenol and iodoform, designed for sustained release, antimicrobial activity, and pain relief in alveolar osteitis (AO).

Methods

Formulations with varying ratios of phosphatidylcholine (PC), sorbitan monooleate (SMO), glyceryl monooleate (GMO), and N-methyl-2-pyrrolidone (NMP) were prepared. The formulation which showed a good physicochemical stability and suitable viscosity was selected for further studies (F17, the optimized formulation). The optimized formulation was characterized for physicochemical properties and in vitro release. In a double-blind, randomized trial with 60 AO patients, the LLC-dressing was compared to Alvogyl® for pain, analgesic use, and dressing applications over seven days.

Results

The optimized formulation (F17) contained 35.25% PC, 35.25% SMO, 13.7% eugenol, and 15.8% iodoform, demonstrating an improved sustained drug release profile, appropriate viscosity, effective antibacterial activity, 100% encapsulation efficiency, and drug loading of 13.7% (eugenol) and 15.8% (iodoform). Visual Analog Scale (VAS) pain scores were comparable between LLC-dressing and Alvogyl® at all assessed time points, with no significant differences (0 h: 8.14 ± 1.40 vs. 7.96 ± 1.02; 7 days: 0.70 ± 0.66 vs. 0.78 ± 0.60; p > 0.05). Analgesic use (5.51 ± 3.06 vs. 6.13 ± 2.87, P = 0.401) and dressing applications (2.27 ± 1.12 vs. 2.57 ± 1.20, P = 0.345) showed similar efficiency.

Conclusion

The optimized LLC-dressing (F17) exhibits favorable physicochemical and in vitro characteristics and may be considered a potential alternative to Alvogyl® for the management of AO.